Human responses to two decavalent rhinovirus vaccines

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Rhinoviruses are a common cause of respiratory infections.
• Developing effective multivalent vaccines against numerous rhinovirus serotypes remains a challenge.

Purpose of the Study:

• To evaluate the acceptability and antigenicity of two formalin-inactivated, decavalent rhinovirus vaccines in human subjects.
• To assess the safety and immunogenicity of these candidate vaccines.

Main Methods:

• Human subjects received two formalin-inactivated, decavalent rhinovirus vaccines.
• Vaccine acceptability, side effects, and antigenic responses were monitored.
• Infectivity titers of vaccine antigens were determined using 50% tissue culture infective doses (TCID50/ml).

Main Results:

• Both vaccines were well-tolerated with minimal or no reported side effects.
• Antigenicity was low, with one vaccine eliciting responses to only 30% of administered antigens.
• Low infectivity titers (10^1.5 to 10^5.5 TCID50/ml) were observed for vaccine antigens.

Conclusions:

• Current formalin-inactivated, decavalent rhinovirus vaccines demonstrate acceptable safety but limited immunogenicity.
• Future vaccine development should focus on increasing antigen potency and selecting for cross-reactivity to achieve broader protection.
• Further investigation into potent multivalent rhinovirus vaccines is crucial for practical control measures.